Search results
Showing 361 to 375 of 451 results for chronic pain
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.
We have moved Medical technologies guidance 41 to become HealthTech guidance 498. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)
This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.
This process guide provides an overview of the key principles used for developing NICE decision aids. It ensures that robust, quality-assured decision aids for people using and providing health and social care services are developed in an open, transparent and timely way, with appropriate input from key groups
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)
Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.
This guideline covers exercise referral schemes for people aged 19 and older, in particular, those who are inactive or sedentary. The aim is to encourage people to be physically active.
Delirium: prevention, diagnosis and management in hospital and long-term care (CG103)
This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)
Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults
Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)
Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.
Spesolimab for treating generalised pustular psoriasis flares (TA1070)
Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.